Conexeu Sciences (CNXU) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Conexeu Sciences is the larger company by market cap ($109.7 million vs $97.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNXU | OKUR |
|---|---|---|
| Share price | $3.89 | $2.41 |
| Market cap | $109.72M | $97.60M |
| 1-day change | +12.75% | +4.78% |
| YTD return | — | -16.90% |
| 1-year return | — | -23.00% |
| 5-year return | — | -96.26% |
| EPS (TTM) | $-0.61 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.79 | $5.38 |
| 52-week low | $3.05 | $2.13 |
| Distance from 52-week high | -79.30% | -55.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +414.14% | +543.15% |
| Average volume | 211.83K | 223.45K |
| Shares outstanding | 28.21M | 40.50M |
| Employees | — | 45 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Conexeu Sciences
CNXU stock →Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair.
Health Care · Industrial Specialties
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
CNXU vs OKUR FAQ
Which is bigger, Conexeu Sciences or OnKure Therapeutics?
Conexeu Sciences (CNXU) is larger, with a market capitalization of $109.72M compared with $97.60M for OnKure Therapeutics (OKUR).
Are Conexeu Sciences and OnKure Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Conexeu Sciences and Biotechnology: Pharmaceutical Preparations for OnKure Therapeutics.